CoChat
Sign Up
Cited by 1,037Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.

Tau pathology in Alzheimer disease and other tauopathies

Open access
Iqbal, Khalid, del C. Alonso, Alejandra, Chen, She, Chohan, M. Omar, El-Akkad, Ezzat, Gong, Cheng-Xin, Khatoon, Sabiha, Li, Bin, Liu, Fei, Rahman, Abdur, Tanimukai, Hitoshi, Grundke-Iqbal, Inge·2005·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
DOI 10.1016/j.bbadis.2004.09.008
Open this paper in CoChat — free account

Abstract

Just as neuronal activity is essential to normal brain function, microtubule-associated protein tau appears to be critical to normal neuronal activity in the mammalian brain, especially in the evolutionary most advanced species, the homo sapiens. While the loss of functional tau can be compensated by the other two neuronal microtubule-associated proteins, MAP1A/MAP1B and MAP2, it is the dysfunctional, i.e., the toxic tau, which forces an affected neuron in a long and losing battle resulting in a slow but progressive retrograde neurodegeneration. It is this pathology which is characteristic of Alzheimer disease (AD) and other tauopathies. To date, the most established and the most compelling cause of dysfunctional tau in AD and other tauopathies is the abnormal hyperphosphorylation of tau. The abnormal hyperphosphorylation not only results in the loss of tau function of promoting assembly and stabilizing microtubules but also in a gain of a toxic function whereby the pathological tau sequesters normal tau, MAP1A/MAP1B and MAP2, and causes inhibition and disruption of microtubules. This toxic gain of function of the pathological tau appears to be solely due to its abnormal hyperphosphorylation because dephosphorylation converts it functionally into a normal-like state. The affected neurons battle the toxic tau both by continually synthesizing new normal tau and as well as by packaging the abnormally hyperphosphorylated tau into inert polymers, i.e., neurofibrillary tangles of paired helical filaments, twisted ribbons and straight filaments. Slowly but progressively, the affected neurons undergo a retrograde degeneration. The hyperphosphorylation of tau results both from an imbalance between the activities of tau kinases and tau phosphatases and as well as changes in tau's conformation which affect its interaction with these enzymes. A decrease in the activity of protein phosphatase-2A (PP-2A) in AD brain and certain missense mutations seen in frontotemporal dementia promotes the abnormal hyperphosphorylation of tau. Inhibition of this tau abnormality is one of the most promising therapeutic approaches to AD and other tauopathies.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bbadis.2004.09.008

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 154 references

Cited by

Sorted by citations

Items 501–600 of 999

Related

See all

Metadata

Authors
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., Tanimukai, H., & Grundke-Iqbal, I.
Affiliations
New York State Office for People With Developmental Disabilities (US)
Corresponding author
Iqbal, Khalid
ORCID
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Publisher
Elsevier BV
Published
2005-01
Volume
1739
Issue
2-3
Pages
198-210
ISSN
0925-4439 (ISSN-L)
DOI
10.1016/j.bbadis.2004.09.008
OpenAlex
W1998440070
Cited by
1,037
References
154
Citations by year
2026: 28 · 2025: 48 · 2024: 50 · 2023: 67 · 2022: 60 · 2021: 60 · 2020: 57 · 2019: 58 · 2018: 64 · 2017: 48 · 2016: 48 · 2015: 54 · 2014: 52 · 2013: 48 · 2012: 52
FWCI
3.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (AG19158, R01AG019158)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
tau protein, tauopathy, Alzheimer's disease, tau hyperphosphorylation, neurofibrillary tangles, paired helical filaments, microtubule stabilization, MAP2, tau kinases, protein phosphatase 2A, frontotemporal dementia, tau conformation, neurodegeneration, tau dephosphorylation, tau-targeted therapy
MeSH terms
Alzheimer Disease, Brain, Enzyme Inhibitors, Humans, Models, Biological, Nerve Degeneration, Neurofibrils, Phosphoprotein Phosphatases, Phosphorylation, Protein Conformation, Protein Kinases, Neurofibrillary Tangles, tau Proteins, Tauopathies, Protein Phosphatase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review